SYRE biotech catalysts & pipeline

SPYRE THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

SPY001 — Topline data

in 2026

Part A: Open-label assessment of the safety and preliminary efficacy of a single dose level of each investigational monotherapy, with induction data expected in 2026.

Source filing

SPY003 — Topline data

Sep 2026

Enrollment for Part A has completed, with SPY001 and SPY002 Part A topline induction data announced in Q2 2026, and topline data expected for SPY003 in September 2026.

Source filing

SPY072 — Topline data

Q4 2026

Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028

Source filing

monotherapies and combinations — Topline data

2027

Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept, and contribution of components for combinations, with induction data expected in 2027.

Source filing

SPY001 — Topline data

in 2027

Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept and contribution of components for combinations, with induction data expected in 2027.

Source filing

SPY001, SPY002, SPY003 SPY120, SPY130, SPY230 — Topline data

2027

SKYLINE Part B Ulcerative Colitis SPY001, SPY002, SPY003 SPY120, SPY130, SPY230 2027

Source filing

SPY002 (anti-TL1A) — Topline data

next year

We have begun enrolling these combinations globally and look forward to unveiling proof-of-concept data next year.

Source filing

SPY003 — Topline data

2027

Part B: Randomized and placebo-controlled assessment of the safety and efficacy of monotherapies and combinations, designed to provide dose-ranging data on monotherapies, proof-of-concept and contribution of components for combinations, with induction data expected in 2027.

Source filing

SPY072 + IL17-A/F — Topline data

Sep 2027–Apr 2028

Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028

Source filing

Explore the free biotech catalyst calendar